| 孙晓慧.匹多莫德辅助应用对小儿支气管哮喘肺功能及免疫功能的影响[J].安徽医药,2019,23(2):364-367. |
| 匹多莫德辅助应用对小儿支气管哮喘肺功能及免疫功能的影响 |
| Effect of Pidotimod on the lung function and immune function in children with bronchial asthma |
| 投稿时间：2017-07-04 |
| DOI： |
| 中文关键词: 匹多莫德 小儿支气管哮喘 肺功能 免疫功能 |
| 英文关键词: Pidotimod Bronchial asthma Pulmonary function Immune function |
| 基金项目: |
|
| 摘要点击次数: 1700 |
| 全文下载次数: 507 |
| 中文摘要: |
| 目的 探讨匹多莫德辅助应用对小儿支气管哮喘肺功能以及免疫功能的影响。方法 选取2015年2月至2016年2月临清市人民医院接受治疗的小儿支气管哮喘患儿92例,采用随机数表法将所有入选患儿分为对照组和观察组,每组各46例。对照组患儿给予哈西奈德吸入常规治疗,观察组在此基础上给予患儿匹多莫德治疗,观察两组患儿治疗前后T淋巴细胞、血清免疫球蛋白 A(IgA)、免疫球蛋白 G(IgG)以及免疫球蛋白M(IgM)水平表达,比较两组患儿治疗前后肺功能改善情况以及治疗后的临床效果。结果 治疗后,两组患儿的血清水平IgA、IgG以及IgM均有所升高,且观察组患儿IgA、IgG以及IgM分别为(6.56±1.28) 、(10.56±3.02)、(6.89±1.90) g/L,明显高于对照组的(5.43±1.25)、(8.98±2.14)、(5.64±1.68) g/L,差异有统计学意义(P<0.05)；治疗后,两组患儿的CD4+以及 CD4+/CD8+表达水平均有所升高,观察组(35.02±7.12)%、(1.82±0.32)%高于对照组(28.90±6.88)%、(1.46±0.25)%,两组比较均差异有统计学意义(t=4.192, 6.013,均P<0.001)；治疗后,两组患儿的CD8+水平表达都有所降低,观察组(24.56±6.38)%低于对照组(29.12±8.02)%,两组比较差异有统计学意义(t=3.017,P=0.003)；治疗后,两组患儿的肺功能指标用力肺活量、第一秒用力呼气容积以及最大呼气流量均有所提高,且观察组高于对照组,两组比较差异有统计学意义(均P<0.05)；治疗后,观察组患儿总有效率93.48%高于对照组71.73%,两组比较差异有统计学意义(t=7.565,P=0.005)。结论 采用匹多莫德辅助治疗小儿支气管哮喘患儿,能够有效提高患儿的肺功能,改善患儿的免疫功能,值得临床推广使用。 |
| 英文摘要: |
| Objective To investigate the effect of Pidotimod on pulmonary function and immune function in children with bronchial asthma.Methods Ninety-two children with bronchial asthma who were treated in Linqing People's Hospital from February 2015 to February 2016 were selected.All the children were assigned into observation group and control group with 46 cases in each group by random number table method.The control group was given routine treatment,while the observation group was given additionally Pidotimod treatment.The levels of Tlymphocyte,serum immunoglobulin A (IgA),immunoglobulin G (IgG) and immunoglobulin M (IgM) were observed before and after treatment.The improvement of pulmonary function and clinical effects of the two groups were compared before and after treatment.Clinical effects after treatment were compared between the two groups.Results After treatment,the serum levels of IgA,IgG and IgM in the two groups increased,and the levels of IgA,IgG and IgM in the observation group [(6.56±1.28),(10.56 ±3.02),(6.89±1.90) g/L,respectively] were significantly higher than those in the control group [(5.43±1.25),(8.98±2.14),(5.64±1.68) g/L,respectively] (P<0.05).After treatment,the expression levels of CD4+ and CD4+/CD8+ in the two groups were increased,and the expression levels of CD4+ and CD4+/CD8+ in the observation group [(35.02±7.12)%,(1.82±0.32)%,respectively] were significantly higher than those in the control group [(28.90±6.88)%,(1.46±0.25)%,respectively] (t=4.192,6.013,all P=0.001).After treatment,the expression levels of CD8+ in the two groups were decreased,and the level of CD8+ in the observation group was significantly lower than that in the control group [(24.56±6.38)% vs.(29.12±8.02)%] (t=3.017,P=0.003).After treatment,the forced vital capacity,the first second forced expiratory volume and the maximum expiratory flow of the two groups were all improved,and the indexes in the observation group were higher than those in the control group,and the difference was statistically significant (P<0.05).After treatment,the total effective rate of the observation group (93.48%) was higher than 71.73% of the control group,and the difference between the two groups was statistically significant (t=7.565,P=0.005).Conclusions Pidotimod can effectively improve the pulmonary function and immune function of children with bronchial asthma,which is worthy of clinical application and promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
